Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer

Clinical Lung Cancer

Volumn 6, Issue 5, 2005, Pages 314-316

  Langer, Corey J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Bisphosphonates; Bone progression; Economic burden; Skeletal related event; Squamous cell carcinoma

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; GEMCITABINE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; NAPROXEN; PACLITAXEL; TIRAPAZAMINE; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BRACHYTHERAPY; BRAIN METASTASIS; BRONCHOSCOPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; NEEDLE BIOPSY; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHROPATHY; PLEURA EFFUSION; SQUAMOUS CELL CARCINOMA; THORACOCENTESIS; THORAX DRAINAGE; THORAX RADIOGRAPHY;

EID: 20744455227     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.012     Document Type: Article

References (17)

1. Michel F, Soler M, Imhof E, et al. Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax 1991; 46:469-473.
2. Tornyos K, Garcia O, Karr B,et al. A correlation study of bone scanning with clinical and laboratory findings in the staging of nonsmall-cell lung cancer. Clin Nucl Med 1991; 16:107-109.
3. Salvatierra A, Baamonde C, Llamas JM, et al. Extrathoracic staging of bronchogenic carcinoma. Chest 1990; 97:1052-1058.
4. Turner P, Haggith JW. Preoperative radionuclide scanning in bronchogenic carcinoma. Br J Dis Chest 1981; 75:291-294.
5. Hooper RG, Beechler CR, Johnson MC. Radioisotope scanning in the initial staging of bronchogenic carcinoma. Am Rev Respir Dis 1978; 118:279-286.
6. Ramsdell JW, Peters RM, Taylor AT, et al. Multiorgan scans for staging lung cancer: correlation with clinical evaluation. J Thorac Cardiovasc Surg 1977; 73:653-659.
7. Kosteva J, Langer CJ. Incidence and distribution of skeletal metastases in NSCLC in the era of PET scan imaging. Lung Cancer 2004; 46:(suppl 1):S45.
8. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19:61-77.
9. Weder W, Schmid RA, Bruchaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998; 66:886-892.
10. Pieterman RM, van Putten J, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med 2000; 343:254-261.
11. Bury T, Barreto A, Daenan F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25:1244-1247.
12. Marom E, McAdams HP, Erasmus J, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212:803-809.
13. Hetzel M, Arslandemir C, Konig H, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003; 18:2206-2214.
14. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004; 67:390-396.
15. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150-3157.
16. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung cancer and other solid tumors: a randomized, phase III double-blind placebo-controlled trial. Cancer 2004; 100:2613-2621.
17. Hirsh V, Tchekmedyian NS, Rosen LS, et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004; 6:170-174.